Table of Contents

Review Articles

by Hairong Wei, Weiming Wan, Hui Zhan, Jiansong Wang, Jian Chen
31 Views, 2 PDF Downloads

Bladder cancer is the most common malignant tumor of the urinary system. The muscle-invasive bladder cancer (MIBC) is associated with poor prognosis; therefore, new systemic treatment is urgently needed. Although the prognosis of non-muscle-invasive bladder cancer (NMIBC) is relatively good, it is highly recurrent and requires lifelong monitoring that brings huge burden to patients and medical services. Thus, improving the diagnosis and treatment of bladder cancer is still a very important milestone to achieve. Fibroblast growth factor receptor 3 (FGFR3) gene mutations frequently occur in bladder cancer. The mutations are related to the development, progression, and prognosis of bladder cancer and may serve as effective biomarkers and therapeutic targets. An increase in the understanding of FGFR3 in recent years is expected to lead to new insights into the diagnosis and treatment of bladder cancer, thereby prolonging the survival of patients. Combined with relevant clinical research and basic research, this article reviews the application of FGFR3 in the diagnosis and treatment of bladder cancer.